News | May 28, 2009

Lantheus Completes Enrollment for Echocardiography Trial

May 28, 2009 - Lantheus Medical Imaging Inc. has completed patient enrollment of CaRES (Contrast Echocardiography REgistry for Safety Surveillance), the first, multicenter Phase IV observational registry that evaluates the use of ultrasound imaging agents in routine clinical practice. The 1,060 patients who were enrolled at 15 sites in the U.S. were 18 years old or older and required DEFINITY Vial for (Perflutren Lipid Microsphere) injectable suspension-enhanced echocardiography because of a previous suboptimal, unenhanced echocardiogram.

"As the first, multicenter safety registry of its kind to be conducted in the U.S., the results from CaRES will provide important clinical information about the use of DEFINITY in a range of patient types and clinical settings,” said Mark Hibberd, M.D., senior medical director, Lantheus Medical Imaging, Inc. “We expect these findings to reveal that DEFINITY is being used in the settings recommended in the recent American Society of Echocardiography Consensus Statement[i], and that these uses are well tolerated. The use of DEFINITY in appropriate settings, such as in-hospital and intensive care units, can assist physicians in making immediate point-of-care decisions, as recently shown by Kurt et al[ii] and in doing so, can help reduce the use of other more costly tests and direct medical therapy to meet patient needs.”

The CaRES registry was established following discussions with the FDA to further explore the clinical use of DEFINITY. The prospective, open-label, non-randomized, Phase IV surveillance registry will gather and analyze data on: patient demographics and characteristics, reasons for using DEFINITYÒ, results of safety monitoring, and the nature and frequency of any adverse events.

[i] Mulvagh SL et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr. 2008; vol. 21 no. 11: 1179-1201

[ii] Kurt M et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospect cohort. J Am Coll Cardiol. 2009; 53: 802-810

For more information: www.lantheus.com

Related Content

Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...